MCID: VSL004
MIFTS: 28

Visual Cortex Disease malady

Categories: Eye diseases

Aliases & Classifications for Visual Cortex Disease

Aliases & Descriptions for Visual Cortex Disease:

Name: Visual Cortex Disease 12 14
Visual Cortex Dysfunction 12
Visual Cortex Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5691
ICD10 33 H47.6
ICD9CM 35 377.7
NCIt 47 C35275
UMLS 69 C0234398

Summaries for Visual Cortex Disease

MalaCards based summary : Visual Cortex Disease, also known as visual cortex dysfunction, is related to penis sarcoma and brody myopathy. An important gene associated with Visual Cortex Disease is IER3IP1 (Immediate Early Response 3 Interacting Protein 1). The drugs Dexamethasone and Betamethasone have been mentioned in the context of this disorder. Affiliated tissues include cortex and eye, and related phenotypes are pigmentation and vision/eye

Related Diseases for Visual Cortex Disease

Graphical network of the top 20 diseases related to Visual Cortex Disease:



Diseases related to Visual Cortex Disease

Symptoms & Phenotypes for Visual Cortex Disease

MGI Mouse Phenotypes related to Visual Cortex Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.13 CLN8 DOCK7 MFSD8
2 vision/eye MP:0005391 9.02 CLN6 CLN8 DOCK7 MFSD8 PRNP

Drugs & Therapeutics for Visual Cortex Disease

Drugs for Visual Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
2
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
3
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Choline Approved, Nutraceutical Phase 4 62-49-7 305
7 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
8 calcium channel blockers Phase 4,Phase 3,Phase 2
9 Narcotics Phase 4,Phase 2
10 Analgesics, Opioid Phase 4,Phase 2
11 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
19 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
21 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Calcium, Dietary Phase 4,Phase 3,Phase 2
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
24
Imidacloprid Phase 4 105827-78-9 86418
25 Betamethasone Valerate Phase 4 2152-44-5
26 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
27
Fluticasone Phase 4,Phase 3 90566-53-3, 80474-14-2 62924 22833648
28 glucocorticoids Phase 4,Phase 3,Phase 2
29
protease inhibitors Phase 4,Phase 3
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 HIV Protease Inhibitors Phase 4,Phase 3
33 Nootropic Agents Phase 4
34 Norgestimate, ethinyl estradiol drug combination Phase 4
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
36 Dermatologic Agents Phase 4,Phase 3,Phase 2
37 Homatropine Phase 4
38 Hormone Antagonists Phase 4,Phase 3,Phase 2
39 Dexamethasone 21-phosphate Phase 4,Phase 3
40 Hormones Phase 4,Phase 3,Phase 2
41 Parasympatholytics Phase 4
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
43 Anti-Allergic Agents Phase 4,Phase 3
44 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
45 Antiemetics Phase 4,Phase 3,Phase 1
46 BB 1101 Phase 4,Phase 3
47 Betamethasone benzoate Phase 4
48 Betamethasone sodium phosphate Phase 4
49 Betamethasone-17,21-dipropionate Phase 4
50 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 281)
id Name Status NCT ID Phase
1 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
2 Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and "Normal" Patients Completed NCT02604953 Phase 4
3 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
4 Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation Completed NCT00241566 Phase 4
5 Phase Out in Tinnitus Patients Completed NCT00833950 Phase 4
6 A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00682643 Phase 4
7 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03046693 Phase 4
8 Perioperative Mirror Therapy and Phantom Limb Pain Recruiting NCT02383979 Phase 4
9 Treatment of the Symptomatic Sacral Perineurial Cysts Recruiting NCT02595190 Phase 4
10 Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome Terminated NCT01261650 Phase 4
11 Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine Unknown status NCT02122757 Phase 3
12 Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke Unknown status NCT01000103 Phase 3
13 Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions Unknown status NCT01418820 Phase 2, Phase 3
14 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
15 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
16 RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine Completed NCT02122744 Phase 3
17 Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Completed NCT02122237 Phase 3
18 Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve) Completed NCT01282827 Phase 2, Phase 3
19 Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma Completed NCT00254956 Phase 3
20 Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07 Completed NCT01447719 Phase 3
21 ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation Completed NCT01649232 Phase 3
22 Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps Completed NCT02024659 Phase 2, Phase 3
23 Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia Completed NCT02358902 Phase 2, Phase 3
24 Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence Completed NCT02557815 Phase 3
25 Effects of Repetitive Transcranial Magnetic Stimulation in the Treatment of Phantom Limb Pain in Landmine Victims: ANTARES Completed NCT01872481 Phase 3
26 A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma Completed NCT00434161 Phase 3
27 Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS) Completed NCT00309387 Phase 3
28 Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis Completed NCT03140449 Phase 3
29 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed NCT01018186 Phase 3
30 Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study Recruiting NCT02362880 Phase 2, Phase 3
31 Neurostimulation and Cognitive Intervention in Alzheimer's Disease Recruiting NCT02772185 Phase 2, Phase 3
32 Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain Recruiting NCT02311777 Phase 3
33 Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia Recruiting NCT02778906 Phase 3
34 PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns Recruiting NCT03079167 Phase 3
35 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00549848 Phase 3
36 CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain Terminated NCT00122915 Phase 3
37 Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability Withdrawn NCT02212613 Phase 3
38 Does tDCS is Effective in the Prophylactic Treatment of Migraine Unknown status NCT01886274 Phase 2
39 Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Unknown status NCT02300818 Phase 1, Phase 2
40 Association of Functional Changes in the Brain and the Perception of Pain in Patients With Chronic Inflammatory Bowel Diseases (IBD) Unknown status NCT02433470 Phase 2
41 Functional Neuroimaging in Fibromyalgia Patients Receiving tDCS Unknown status NCT01904097 Phase 2
42 THE EFFECT OF tDCS IN THE TREATMENT OF CHRONIC PELVIC PAIN ASSOCIATED WITH ENDOMETRIOSIS Unknown status NCT02161302 Phase 2
43 Transcranial Direct Current Stimulation (tDCS) for the Treatment of Tinnitus Unknown status NCT01575496 Phase 2
44 Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia Unknown status NCT02104752 Phase 1, Phase 2
45 Evaluation of the Potentiating Effect of tDCS on Opioid Analgesia of Pain Threshold in Humans Unknown status NCT02432677 Phase 2
46 Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease Completed NCT01275573 Phase 2
47 Trial of Alternating Current Stimulation in Optic Neuropathy Completed NCT01270126 Phase 2
48 Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD) Completed NCT01196624 Phase 2
49 Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study Completed NCT02935413 Phase 1, Phase 2
50 Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study Completed NCT02703870 Phase 1, Phase 2

Search NIH Clinical Center for Visual Cortex Disease

Genetic Tests for Visual Cortex Disease

Anatomical Context for Visual Cortex Disease

MalaCards organs/tissues related to Visual Cortex Disease:

39
Cortex, Eye

Publications for Visual Cortex Disease

Variations for Visual Cortex Disease

Expression for Visual Cortex Disease

Search GEO for disease gene expression data for Visual Cortex Disease.

Pathways for Visual Cortex Disease

GO Terms for Visual Cortex Disease

Biological processes related to Visual Cortex Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cholesterol metabolic process GO:0008203 9.26 CLN6 CLN8
2 protein catabolic process GO:0030163 9.16 CLN6 CLN8
3 cellular macromolecule catabolic process GO:0044265 8.96 CLN6 CLN8
4 lysosome organization GO:0007040 8.8 CLN6 CLN8 MFSD8

Sources for Visual Cortex Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....